Cannabinoid Receptor

Receptor

Cannabinoid Receptor Isoform Specific Products:

Cannabinoid Receptor Related Products (382)
Antibodies (1)
Cannabinoid Receptor Isoform Comparison

By Effects:	Controls (2) Inhibitors (30) Ligands (8) Agonists (113) Antagonists (64) Activators (12) Modulators (21) Chemical (1)

Cat. No.	Product Name	Effect	Purity	Chemical Structure

HY-172808

BNS808	Antagonist
BNS808 is an orally active and selective cannabinoid-1 receptor (CB₁R) antagonist (IC₅₀ = 0.8 nM) with notable CB₂R selectivity and minimal brain penetration. BNS808 is studied in research on obesity and its associated metabolic complications, such as metabolic dysfunctional-associated steatotic liver disease (MASLD). BNS808 has reduced free drug availability for CNS entry, enhancing safety and minimizing drug-drug interactions through high plasma binding.

HY-125407

Palmitoyl serinol
Palmitoyl serinol (N-Palmitoyl serinol) is an analog of the endocannabinoid N-palmitoyl ethanolamine (PEA). Palmitoyl serinol improves the epidermal permeability barrier in both normal and inflamed skin.

HY-150030

CB1/2 agonist 4	Agonist
CB1/2 agonist 4 is a full CB1 agonist and CB2 partial agonist with EC₅₀ values of 15.09 nM and 1.16 nM, respectively. CB1/2 agonist 4 also has hCB1 and hCB2 receptor affinities with K_i values of 1.1 nM and 4.2 nM, respectively. CB1/2 agonist 4 has a significant antinociceptive activity, and also can activate cannabinoid and TRPV1 receptor with values of IC₅₀ and EC₅₀ is 0.8 μM and 0.12 μM, respectively.

HY-110048

O-2545 hydrochloride	Activator
O-2545 hydrochloride is a highly potent, water-soluble CB1/CB2 receptor agonist (with K_i values of 1.5 and 0.32 nM for CB1 and CB2 respectively), can be used for epilepsy, pain, multiple sclerosis research.

HY-120300

UCM710	Inhibitor
UCM710 is an endocannabinoid (eCB) hydrolysis inhibitor that increases the levels of N-arachidonoyl ethanolamine and 2-arachidonoylglycerol in neurons. UCM710 inhibits fatty acid amide hydrolase and α/β-hydrolase domain 6, but not monoacylglycerol lipase.

HY-107019

Surinabant	Antagonist
Surinabant (SR 147778) is an orally active, selective cannabinoid receptor type 1 CB1R antagonist. Surinabant is used in studies of obesity and alcoholism.

HY-110020

rel-O-2050	Antagonist
rel-O-2050 (Compound O-2050) is a neutral cannabinoid CB₁ receptor antagonist. rel-O-2050 also decreases food intake in mice.

HY-152251

CB2R/FAAH modulator-1	Agonist
CB2R/FAAH modulator-1 is a cannabinoid type 2 receptor (CB2R) full agonist with K_is of 14.8 nM and 241.3 nM for CB2R and CB1R, respectively. CB2R/FAAH modulator-1 is a fatty acid amide hydrolase (FAAH) inhibitor with an IC₅₀ of 4 μM. CB2R/FAAH modulator-1 decreases pro-inflammatory and increases anti-inflammatory cytokines production.

HY-148850

AZD-2207	Antagonist
AZD-2207 is a cannabinoid receptor CB1 antagonist, known for its high lipophilicity. AZD-2207 has good intestinal permeability in the Caco-2 model and can be used in research related to type 2 diabetes and obesity.

HY-W013788R

2-Palmitoylglycerol (Standard)	Agonist
2-Palmitoylglycerol (Standard) is the analytical standard of 2-Palmitoylglycerol. This product is intended for research and analytical applications. 2-Palmitoylglycerol (2-Palm-Gl), an congener of 2-arachidonoylglycerol (2-AG), is a modest cannabinoid receptor CB1 agonist. 2-Palmitoylglycerol also may be an endogenous ligand for GPR119.

HY-150028

CB1/2 agonist 2	Agonist
CB1/2 agonist 2 (compound 23) is a potent non-selective cannabinoid ligand, with K_i values of 3.5 and 1.2 nM, respectively. CB1/2 agonist 2 can behave as a full CB1 agonist and CB2 competitive inverse agonist. CB1/2 agonist 2 shows antinociceptive activity.

HY-147559

CB1R Allosteric modulator 2	Modulator
CB1R Allosteric modulator 2 (compound 18) is a potent CB1R allosteric modulator. CB1R Allosteric modulator 2 shows negatively affects the functional activity of orthosteric ligands (NAM) at CB1Rs.

HY-144705

GAT564	Modulator
GAT564 (Compound 15d) is a potent allosteric modulator of cannabinoid 1 receptor (CB1R) with EC₅₀s of 87 and 320 nM respectively for cAMP and β-arrestin2. GAT564 markedly promotes orthosteric ligand binding to hCB1R. GAT564 is efficacious as a topical agent that significantly reduces intraocular pressure (IOP) in the ocular normotensive murine model of glaucoma.

HY-147558

CB1R Allosteric modulator 1	Modulator
CB1R Allosteric modulator 1 (compound 11) is a potent CB1R allosteric modulator. CB1R Allosteric modulator 1 shows negatively affects the functional activity of orthosteric ligands (NAM) at CB1Rs.

HY-149933

AM841	Activator
AM841 is a high-affinity electrophilic ligand. AM841 interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. AM841 reduces Forskolin (HY-15371)-stimulated cAMP accumulation. AM841 also slows gastrointestinal motility.

HY-N15177

Δ9-THCB	Agonist
Δ9-THCB (Δ9-Tetrahydrocannabutol) has a high affinity for human CB1 and CB2 receptors with the K_i values of 15 nM and 51 nM, respectively. Δ9-THCB (Δ9-Tetrahydrocannabutol) has analgesic and anti-inflammatory activities and plays partial agonistic effects on CB1 receptor in mice.

HY-134615

Mead ethanolamide	Agonist
Mead ethanolamide is an endogenous cannabinoid receptor agonist with K_d values of 753 nM and 1810 nM against CB1 and CB2, respectively.

HY-103340

O-2093
O-2093 is a selective endocannabinoid anandamide (AEA) reuptake inhibitor with IC₅₀ of 17.3 μM.

HY-W337358

N-(3-Hydroxyphenyl)-arachidonoyl amide	Inhibitor
N-(3-Hydroxyphenyl)-arachidonoyl amide (Compound 23) is an anandamide transport inhibitor with an IC₅₀ of 21.3 μM.

HY-122109A

Levonantradol hydrochloride	Agonist
Levonantradol (l-Nantradol) hydrochloride is an analog of delta (9)-tetrahydrocannabinol. Levonantradol acting as a potent anti-analgesic agent.

Anandamide	CB1	CB2	≥99.0%
Rimonabant	CB1 , Ki: 1.8 nM		99.18%
Pregnenolone	CB1		99.87%
SR144528		CB2	99.25%
JD-5037	CB1 , IC₅₀: 1.5 nM		99.38%
Rimonabant Hydrochloride	CB1 , Ki: 1.8 nM		99.79%
Pregnenolone monosulfate sodium	CB1		99.96%
Synaptamide	CB1 , Ki: 633 nM	CB2 , Ki: 3843 nM	99.30%
Leelamine	CB1	CB2	98.36%
Yangonin	CB1 , IC₅₀: 1.79 μM CB1 , Ki: 0.72 μM		99.79%
N-Oleoyl glycine	CB1		≥99.0%
GW-405833	CB1 , EC₅₀: 16.1 μM	CB2 , EC₅₀: 50.7 nM	99.12%
Pregnenolone monosulfate	CB1		99.96%
AM281	CB1 , IC₅₀: 9.91 nM	CB2 , IC₅₀: 13000 nM	≥99.0%
Leelamine hydrochloride	CB1		99.06%
Etrinabdione		CB2	99.16%
CB2R PAM		cannabinoid type-2 receptors	98.46%
Tetrahydromagnolol	CB1 , EC₅₀: 9010 nM CB1 , Ki: 2260 nM	CB2 , EC₅₀: 170 nM CB2 , Ki: 416 nM	99.79%
CB1 antagonist 4	CB1		99.00%
SCH 336		hCB2-R	98.85%
Bay 59-3074	CB1 , Ki: 48.3 nM	CB2 , Ki: 45.5 nM	98.60%
CB1/2 agonist 3	hCB1-R, Ki: 5.9 nM	hCB2-R, Ki: 3.5 nM	99.83%
AZD1940	hCB1-R, pKi: 7.93	hCB2-R, pKi: 9.06	99.58%
Pregnenolone (Standard)	CB1
Drinabant	hCB1-R, IC₅₀: 25 nM rCB1-R, IC₅₀: 10 nM	CB2 , IC₅₀: 10000 nM	≥99.0%
Vicasinabin		hCB2-R, EC₅₀: 2.81 nM	98.37%
GW 833972A		hCB2-R, pEC₅₀: 7.3 rat CB2-R, pEC₅₀: 7.5	99.91%
CB1/2 agonist 1	hCB1-R, EC₅₀: 56.15 nM	cannabinoid type-2 receptors, EC₅₀: 11.63 nM	99.20%
GAT211	CB1		99.98%
Auriculasin	CB1 , IC₅₀: 8.92 μM		98.58%
Tedalinab		CB2	99.94%
(R)-Methanandamide	CB1 , Ki: 20 nM
CB2R antagonist 3		CB2R	98.08%
Ibipinabant	CB1 , Ki: 7.8 nM	CB2 , Ki: 7943 nM	99.90%
CB2 modulator 1		CB2	99.75%
PGN36		cannabinoid type-2 receptors, Ki: 0.09 μM	99.74%
CB1 inverse agonist 2	CB1 , pKi: 9.7	CB2 , pKi: 6.0
2-Palmitoylglycerol	CB1		≥99.0%
RVD-Hpα TFA	CB1		99.32%
Zevaquenabant	CB1		99.62%
ANEB-001	CB1
Dihomo-γ-Linolenoyl Ethanolamide	hCB1-R, Ki: 857 nM	hCB2-R, Ki: 598 nM
Noladin ether	CB1 , Ki: 21.2 nM	CB2 , Ki: >3 mM	≥98.0%
CB2R/FAAH modulator-3	CB1 , Ki: 67.6 nM	CB2 , Ki: 20.1 nM	99.71%
CB2 receptor agonist 2		CB2 , Ki: 8.5 nM	≥99.0%
Nonabine	CB1		99.95%
URB447	CB1 , IC₅₀: 313 nM		99.5%
L759633	CB1 , Ki: 1043 nM	CB2 , Ki: 6.4 nM	≥99.0%
N-Arachidonyldopamine	CB1 , Ki: 250 nM		98.36%
MJ15	rCB1-R, Ki: 27.2 pM rCB1-R, IC₅₀: 118.9 pM
PSNCBAM-1	hCB1-R, EC₅₀: 0.1 μM		99.48%
AM9405	CB1 , IC₅₀: 45.71 nM
Isopropyl dodec-11-enylfluorophosphonate	CB1 , IC₅₀: 2 μM
(R)-SLV 319	CB1 , Ki: 894 nM
RTICBM-189	CB1 , pIC₅₀: 7.54 hCB₁, pIC₅₀: 5.29 mCB₁, pIC₅₀: 6.25		99.73%
CB2 receptor agonist 9		CB2R, EC₅₀: 16.2 nM
AChE/BChE-IN-18		CB2 , Ki: 31 nM
LY320135	CB1 , Ki: 141 nM	CB2 , Ki: >10 μM
O-2050	CB1 , Ki: 2.5 nM	CB2 , Ki: 0.2 nM
CB2 receptor agonist 8		CB2R
CB1R agonist 1	CB1R, Ki: 0.95 nM
Tocrifluor 1117	CB1
CB1R Allosteric modulator 4	hCB1-R
hBChE-IN-2		hCB2-R, IC₅₀: 0.78 μM
BAY 38-7271	CB1 , Ki: 1.85 nM	CB2 , Ki: 5.96 nM
CB2R-IN-1		CB2 , Ki: 0.9 nM
CB1R Allosteric modulator 3	CB1		98.05%
CB2R agonist 3		CB2R, EC₅₀: 0.37 μM
PSB-SB-1203	CB1 , Ki: 0.244 μM	CB2 , Ki: 0.21 μM
SMM-189		CB2
MDA7	rCB1-R, Ki: 2565 nM	rat CB2-R, IC₅₀: 67.4 nM hCB2-R, IC₅₀: 128 nM rat CB2-R, Ki: 238 nM hCB2-R, Ki: 422 nM
MN-25	CB1 , Ki: 254 nM	CB2 , Ki: 11 nM
CB1/2 receptor-1	CB1	CB2
CBR Agonist-2	hCB1-R, EC₅₀: 960 nM hCB1-R, Ki: 970 nM
CB2R probe 1		cannabinoid type-2 receptors, Ki: 130 nM
(R)-(+)-Linoleyl-1'-Hydroxy-2'-Propylamide	CB1 , Ki: 21 μM	CB2 , Ki: 21 μM
CB2 receptor agonist 6		CB2R
CB2R/FAAH modulator-2	CB1 , Ki: 152.9 nM	CB2 , Ki: 10.8 nM
Docosatetraenylethanolamide	CB1
CB2R agonist 1		CB2R, EC₅₀: 0.56 μM
R-2 Methanandamide	rCB1-R, Ki: 119 nM
TRPV1/CB2 agonist 1		CB2
Amauromine	CB1 , Ki: 178 nM CB1 , Kb: 66.6 nM
CB1R antagonist 1	hCB1-R, IC₅₀: 4.2 μM hCB1-R, EC₅₀: 10 μM		99.89%
BNS808	CB1R, IC₅₀: 0.8 nM
rel-O-2050	CB1
CB2R/FAAH modulator-1	CB1R, Ki: 241.3 nM CB1R, EC₅₀: 489 nM	CB2R, Ki: 14.8 nM CB2R, EC₅₀: 123.6 nM
AZD-2207	CB1
CB1/2 agonist 2	hCB1-R, Ki: 3.5 nM	hCB2-R, Ki: 1.2 nM
CB1R Allosteric modulator 2	hCB1-R
CB1R Allosteric modulator 1	hCB1-R
Δ9-THCB	CB1 , Ki: 15 nM	CB2 , Ki: 51 nM
Mead ethanolamide	CB1 , Kd: 753 nM	CB2 , Kd: 1810 nM
PM226		CB2 , Ki: 13 nM CB2 , EC₅₀: 39 nM
NIDA-41020	CB1 , Ki: 4.1 nM
RVD-Hpα	CB1
CBR Agonist-1	rCB1-R, Ki: 0.18 μM	hCB2-R, Ki: 1.22 μM
AB-FUBICA	CB1 , EC₅₀: 21 nM	CB2 , EC₅₀: 15 nM
MRL-650	CB1 , IC₅₀: 7.5 nM	CB2 , IC₅₀: 4100 nM
Eicosapentaenoyl ethanolamide	CB1	CB2
CB1-IN-2	CB1 , IC₅₀: 0.644 μM
CB1 antagonist 5	hCB₁, EC₅₀: 195 nM hCB₁, Ki: 243 nM
Δ8-THC-C8	CB1 , EC₅₀: 13.8 nM
Δ8-THC methyl ether		CB2
PF-03550096		CB2 , Ki: 7.9 nM
TM38837	CB1
PSB-SB1202	CB1 , EC₅₀: 56 nM CB1 , Ki: 32 nM	CB2 , EC₅₀: 14 nM CB2 , Ki: 49 nM	99.48%
Δ8-THCP	CB1

Name
Email *

	Sorry, but the email address you supplied was invalid.

Cannabinoid Receptor

Cannabinoid Receptor

Cannabinoid Receptor Isoform Specific Products:

Cannabinoid Receptor Isoform Specific Products:

Cannabinoid Receptor Related Products (382)

Antibodies (1)

Cannabinoid Receptor Isoform Comparison

Cannabinoid Receptor Related Products (382):